Allstate Sues Pharmacies Over No-Fault Insurance Fraud in New York
Allstate's lawsuits reveal alleged pharmacy fraud in New York's no-fault insurance system, raising significant concerns for the insurance industry and patient care.
California’s New Bill on Biosimilars: Potential Savings and Implications for Insurers
California's SB 1094 aims to lower healthcare costs with biosimilars, impacting insurance dynamics. Discover potential savings and implications for insurers.
Dompé U.S. Inc. Settles $32M Medicare Co-Pay Allegations
Dompé U.S. Inc. agrees to a $32 million settlement for illegal Medicare co-pay payments, raising critical compliance issues for insurance professionals in the industry.
Texas House Select Committee Addresses Escalating Healthcare Costs
The Texas House Select Committee discusses rising healthcare costs and strategies to enhance pricing transparency and improve rural healthcare access.
Examining the Impact of the Lown Institute's Shkreli Awards on Healthcare Ethics
Explore the Lown Institute's Shkreli Awards spotlighting ethical concerns in healthcare, advocating for transparency and accountability across the industry.
FDA Approves Rasonque: Implications for Insurance Coverage of Cancer Treatments
The FDA’s approval of Rasonque for pancreatic cancer alters health insurance dynamics, emphasizing coverage needs for high-cost therapies. Explore the implications.
GLP-1 Coverage Shifts in Employee Health Plans
Explore the shifting coverage of GLP-1 medications within employee health plans as companies like Cigna and PepsiCo reassess their commitments amid rising costs.
The Cost Implications of GLP-1 Medications on Employer Coverage Strategies
Understanding how the rising cost of GLP-1 medications influences employer coverage strategies in the U.S. amidst increasing demand for weight management treatments.
Medicare Coverage for Statins: Insights for Seniors and Insurance Professionals
Discover how Medicare covers statin therapy for seniors, impacting insurance professionals and their clients managing chronic conditions. Key insights included.
Medicare GLP-1 Bridge Program: A Paradigm Shift in Drug Pricing
Explore the CMS Medicare GLP-1 Bridge program revolutionizing drug pricing for Medicare beneficiaries with a fixed $50 monthly cost.